Notify me when E. David Lazar files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| MINM | FiEE, Inc. | Common Stock, $0.01 par value | 35% | $308,248 | 2,802,254 | -63% | Lazar David E. | 18 Feb 2025 | |
| NBY | NovaBay Pharmaceuticals, Inc. | Common Stock, $0.01 par value | 20% | $2,002,723 | +$402,699 | 1,502,080 | +25% | David E. Lazar | 16 Oct 2025 |
| MTNB | Matinas BioPharma Holdings, Inc. | Common Stock, par value $0.0001 per share | 9.8% | $1,144,500 | 545,000 | Lazar David E. | 15 Aug 2025 | ||
| CYCC | Cyclacel Pharmaceuticals, Inc. | Common Stock, $0.001 par value | 0% | $0 | -$41,481 | 0 | -100% | Lazar David E. | 05 Aug 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|